伊立替康或奥沙利铂联合卡培他滨治疗结直肠癌伴肝转移

Irinotecan or Oxaliplatin Combined With Capecitabine in the Treatment of Colorectal Cancer With Liver Metastasis

目的探讨在结直肠癌伴肝转移患者治疗过程中联合应用卡培他滨与伊立替康或奥沙利铂的临床效果。方法选取2014年6月—2017年6月我院接诊的80例结直肠癌伴肝转移患者纳入本次研究,将结直肠癌伴肝转移患者依照随机数字表法分成奥沙利铂组(n=40)和伊立替康组(n=40),80例患者均接受卡培他滨给药治疗,在此基础上,伊立替康组患者额外接受伊立替康给药治疗,奥沙利铂组患者额外接受奥沙利铂给药治疗。结果奥沙利铂组的客观缓解率(37.50%)、疾病控制率(75.00%)与伊立替康组(35.00%)、(65.00%)相比,差异无统计学意义(P>0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论联合卡培他滨治疗结直肠癌伴肝转移中,伊立替康与奥沙利铂的效果相似。

Objective To investigate the clinical effects of capecitabine(capecitabine)and irinotecan or oxaliplatin(oxaliplatin)in the treatment of colorectal cancer with liver metastases.Methods In this study,80 cases of colorectal cancer accompanied by liver metastases were selected from June 2014 to June 2017 in our hospital.The patients with colorectal cancer with liver metastases were divided into oxaliplatin group(n=40)and erinotecan group(n=40)according to the random number table method.80 patients were treated with capecitabine.On this basis,the erinotecan group receive an extra medication for erinotecan.The oxaliplatin group was treated with oxaliplatin.Results The objective response rate(37.50%)and disease control rate(75.00%)in oxaliplatin group were not significantly different from those in irinotecan group(35.00%,65.00%)(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The effect of irinotecan and oxaliplatin in the treatment of colorectal cancer with liver metastases is similar to that of capecitabine.